• Cyclacel Pharmaceuticals Inc., of Berkeley Heights, N.J., provided new data from a Phase I trial of two product candidates, sapacitabine, a nucleoside analogue, and seliciclib, a CDK inhibitor, as an orally administered sequential treatment regimen in heavily pretreated patients with advanced solid tumors.